<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828046</url>
  </required_header>
  <id_info>
    <org_study_id>MOM-M281-001</org_study_id>
    <nct_id>NCT02828046</nct_id>
  </id_info>
  <brief_title>An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)</brief_title>
  <official_title>A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Momenta Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Momenta Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability, and PK/PD of M281 after single
      and multiple doses in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">August 15, 2017</completion_date>
  <primary_completion_date type="Actual">August 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Counts and Percentages of adverse events by treatment group</measure>
    <time_frame>Baseline until up-to 12 weeks post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of M281 will be summarized using descriptive statistics (arithmetic means, SDs, coefficients of variation, sample size, minimum, maximum, and geometric means).</measure>
    <time_frame>Baseline up-to 12 weeks post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD of M281 will summarize changes in serum markers of inflammation.</measure>
    <time_frame>Up until 12 weeks post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M281</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M281</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M281</intervention_name>
    <arm_group_label>M281</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female subjects between 18 and 55 years, inclusive.

          2. Good health

          3. Body weight between 50 and 110 kg inclusive

        Exclusion Criteria:

          1. History of any drug allergy, hypersensitivity, or intolerance to any drug product that
             in the opinion of the Investigator would place the subject at particular risk and
             compromise the safety of the subject in the study.

          2. History or presence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurologic, oncologic, psychiatric disease, or any other condition, that in the
             opinion of the Investigator would jeopardize the safety of the subject or the validity
             of the study results.

          3. History or current diagnosis of substance dependence (except nicotine and caffeine) or
             alcohol abuse over the past 2 years, according to the criteria of DSM-IV-TR.

          4. Smokes or has smoked more than 5 cigarettes per day in the last 90 days and is unable
             to stop smoking during in-patient observation period in clinic.

          5. Unwillingness to abstain from alcohol for at least 24 hours prior to dosing with study
             medication until the time of discharge from the study unit and at least 24 hours prior
             to each ambulatory visit.

          6. Plans to participate in another clinical trial while enrolled in this study and/or
             received an investigational drug and/or device within 60 days prior to admission.

          7. Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma
             within 14 days prior to admission.

          8. History of splenectomy, asthma (with the exception of childhood asthma that has
             resolved), COPD, recurrent or current GI or respiratory infections.

          9. On fluid restriction.

         10. Systemic steroids within 3 months prior to the start of study drug administration, or
             any prescription medication(s) within 14 days of dose administration or any
             non-prescribed systemic or topical medication (including any herbal product) within 7
             days prior to dose administration.

         11. Vaccination within 1 month before dosing, or plans to receive vaccination during the
             study.

         12. Any illness within 5 days, or clinically significant airway infections within 30 days,
             prior to first study drug dosing.

         13. Positive urine drug screen (UDS) at screening.

         14. Positivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C at
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Hogan, MPM</last_name>
    <role>Study Director</role>
    <affiliation>Momenta Director of Clinical Operations</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tjerk Bosji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Research Physician</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Zuidlaren</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

